- BT1718 progressing in Cancer Research UK sponsored Phase IIa clinical trial - Phase I trial of BT5528 currently dosing within predicted therapeutic range; preliminary signs of anti-tumor activity observed, including a partial response - BT8009 pharmacokinetic profile consistent with preclinical